

GlycoMark®—now you can measure postprandial hyperglycemia and monitor glucose control over 1 to 2 weeks, not months





See a more complete picture of glycemic control for your diabetic patients

Improving glycemic control is paramount to the health of diabetic patients

- Diabetic patients are already at risk for cardiovascular morbidity and mortality¹
- Postprandial hyperglycemia significantly increases cardiovascular risk²

Look beyond the A1C value for a more comprehensive analysis



◆ paired meter glucose readings ▲ meal markers - - - - ADA recommended postmeal glucose target of <180 mg/dL AUC-180=area under the curve for glucose above 180 mg/dL MPMG=mean postmeal maximum glucose

	Patient A	Patient B
A1C	7.43%	7.27%
1,5-AG	12.37 µg/mL	4.5 µg/mL
AUC-180	8 mg/dL ⁻¹ /day ⁻¹	22 mg/dL ⁻¹ /day ⁻¹
MPMG	195 mg/dL	235 mg/dL

GlycoMark—an adjunctive test for physicians to optimize glycemic control

- Bridges the gap between daily monitoring and hemoglobin A1C for moderately and poorly controlled diabetic patients
- Helps monitor short-term hyperglycemia above the renal threshold over a 1- to 2-week period in poorly controlled patients
- For moderately controlled diabetic patients, GlycoMark measures postprandial hyperglycemia, which can provide insight into current treatment plans

“The assessment of postprandial glucose levels and the evaluation of post-meal glucose excursions can...help to tailor the most appropriate treatment for individual patients...”

—Bonora E et al. *Diabetologia*. 2006.³



GlycoMark, used in conjunction with fasting glucose and hemoglobin A1C, provides a more complete picture of glycemic control

DLO—
innovative solutions
to help you manage
your diabetic patients



A complement of diabetes tools to help you every step of the way



GlycoMark® — a valuable and convenient testing addition to your diabetes treatment program

- Measures postprandial glucose changes over a shorter period (1 to 2 weeks) than hemoglobin A1C test²
- Provides information to refine treatment regimen on a more timely basis

A combination of resources and services exclusively from the industry leader

- Ability to consult with endocrinologists at Quest Diagnostics Nichols Institute® on difficult cases
- Availability of online appointment scheduling at most Patient Service Centers
- Email reminder program helps patients comply with diabetes testing

Electronic patient management with the Care360™ Physician Portal

- Secure, 24/7 access to online lab and medication history that can be shared with other providers
- Longitudinal reports track patient and practice-wide trends in lab and medication history



DLO is dedicated to what you do best—caring for your patients

Expect more.™

You and your patients can expect more from DLO.

The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The test is for professional use and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.

References: 1. Diabetes mellitus and disorders of carbohydrate metabolism. In: Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwitz M. *The Merck Manual of Diagnosis and Therapy*. 18th ed. Whitehouse Station, NJ: Merck Research Laboratories; 2006:1274-1291. 2. Dungan KM, Buse JB, Largay J, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. *Diabetes Care*. 2006;29(6):1214-1219. 3. Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. *Diabetologia*. 2006;49(5):846-854.

© Diagnostic Laboratory of Oklahoma. All rights reserved. www.dlolab.com SB2285 12/2007

All third-party marks—® and ™—are the property of their respective owners.

